NFKB1 and COVID-19: To the best of our knowledge, we showed for the first time that all major populations of APC in blood are affected in COVID-19, and that the expression of key markers contributing to immune cell activation, including MyD88, NF-kB, and RANKL, are also impaired in COVID-19 patients.